What You Should Know:
- Inato, a technology platform that connects pharma companies (trial sponsors) with community-based trial sites raises $20M in new funding (A2) led by Cathay Innovation with participation from existing investor Obvious Ventures and new investors La Maison and Top Harvest Capital. Inato works with many of the top 30 pharmaceutical companies worldwide to make clinical trials more inclusive.
- The new funding will fuel Inato’s continued product innovation, international
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Exploring The Value of Metaverse Use Cases in Life Sciences
What once seemed like science fiction, interacting with people across the world has become the new normal. While we have become increasingly accustomed to video calls and instant communication in recent years, forays into virtual worlds and extended realities are still relatively novel.
In a post-Covid world, it seems strange to think that video conferences and calls were not the norm only three years ago. But the value created by virtual interactions during the last several years has
Read More
23andMe, Novartis Launches Pilot for Lipoprotein(a) Education
What You Should Know:
- In support of Lipoprotein(a) Awareness Day, 23andMe, a human genetics and biopharmaceutical company, today announced a collaboration with Novartis to increase awareness for Lipoprotein(a) (Lp(a)).
- High levels of Lp(a) are associated with increased risk of heart attack, stroke and other life threatening conditions. The level of Lp(a), which can be detected through a simple blood test, is almost entirely determined by genes and is unrelated to diet, exercise or
Read More
NVIDIA Unveils Generative AI Service to Advance Life Sciences R&D
What You Should Know:
- NVIDIA today announced an expanded set of generative AI cloud services for customizing AI foundation models to accelerate the creation of new proteins and therapeutics, as well as research in the fields of genomics, chemistry, biology and molecular dynamics.
- Part of NVIDIA AI Foundations, the new BioNeMo™ Cloud service offering — for both AI model training and inference — accelerates the most time-consuming and costly stages of drug discovery. It
Read More
Are Hospitals Ready for Alzheimer’s Treatment Approval?
The FDA’s recent accelerated approval of Leqembi was welcome news across the Alzheimer’s community. However, few health systems, medical practices, or providers are prepared for the extraordinary public interest in a treatment for Alzheimer’s disease – especially not one targeting mild cognitive impairment (MCI) and early dementia due to Alzheimer’s disease – that is likely headed their way soon. The unprecedented scale of the public health and marketing campaigns, the high prevalence of MCI in
Read More
Accelerating Clinical Trials Through AI-Enabled Precision Oncology
The American Cancer Society’s Cancer Statistics 2023 report highlighted a few major accomplishments within oncology, such as decreased cancer mortality rates and increased trial diversity. However, there is still much work to be done. Especially with the multiple types of new and ongoing challenges clinicians and staff members are facing - such as high turnover rates, decreased budgets and increased feelings of burnout - taking the necessary steps to enhance clinical trial procedures is crucial
Read More
Study Confirms mRNA Boosters Extend COVID-19 Protection but Wane Over Time
What You Should Know:
- A nationwide U.S. study of more than 893,000 adults provides solid evidence confirming that mRNA booster immunizations extend protection against moderate and severe COVID for four to five months.
- These findings, published in The BMJ, provide a more complete understanding of the effectiveness and durability of third and fourth doses of the mRNA vaccines, informing policymakers and providing individuals with confirmation of the importance and value of
Read More
Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients
What You Should Know:
- Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance. The price cut goes into effect January 1, 2024.
- The price cut milestone comes in addition to decisions taken in June 2022 to lower diabetes medicines costs: the launch of an unbranded Lantus biologic at -60% versus Lantus list price, and a cap on out-of-pocket costs on insulin to $35 for all people
Read More
Protai Raises $20M to Build an Oncology Drug Discovery Pipeline
What You Should Know:
- Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, today announced a $12 million extension of its seed round, bringing the total amount to $20M.
- The round includes existing investors Grove Ventures and Pitango Healthcare and was joined by Copenhagen-based Maj Invest Equity Fund. The additional funding will be used to build Protai’s oncology drug discovery pipeline, expand data
Read More
Pfizer Acquires Seagen for $43B to Tackle Cancer
What You Should Know:
- Pfizer announced it will acquire biotechnology company Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion. The proposed combination enhances Pfizer’s position as a leading company in Oncology.
Seagen’s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer’s Oncology portfolio.
Seagen Background
Seagen is a pioneer in ADC technology, with
Read More
